Cargando…
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
INTRODUCTION: Anaplastic lymphoma kinase (ALK) inhibitors are the mainstay treatment for patients with non-small cell lung carcinoma (NSCLC) harboring a rearrangement of the ALK gene or the ROS1 oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in di...
Autores principales: | Costa, Rubens Barros, Costa, Ricardo L.B., Talamantes, Sarah M., Kaplan, Jason B., Bhave, Manali A., Rademaker, Alfred, Miller, Corinne, Carneiro, Benedito A., Mahalingam, Devalingam, Chae, Young Kwang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955140/ https://www.ncbi.nlm.nih.gov/pubmed/29774128 http://dx.doi.org/10.18632/oncotarget.25154 |
Ejemplares similares
-
Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis
por: Samacá-Samacá, Daniel, et al.
Publicado: (2023) -
Diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients: A systematic review and meta-analysis
por: Zhang, Xia, et al.
Publicado: (2017) -
Front-line treatment for advanced non-small-cell lung cancer and ALK
fusion: a network meta-analysis
por: Wen, Yaokai, et al.
Publicado: (2022) -
First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis
por: Tao, Jiahao, et al.
Publicado: (2022) -
Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)